Literature DB >> 9620681

TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype.

C King1, J Davies, R Mueller, M S Lee, T Krahl, B Yeung, E O'Connor, N Sarvetnick.   

Abstract

TGF-beta1, expressed in the pancreatic islets, protects the nonobese diabetic (NOD) mouse from insulin-dependent diabetes mellitus (IDDM). The islet antigen-specific T cell response of ins-TGF-beta1 mice relied on different antigen-presenting cells (APC) from those used by NOD T cells. T cells from NOD mice utilized B cells to present islet antigen, whereas T cells from ins-TGF-beta1 mice utilized macrophages. In addition, the islet antigen-specific T cell repertoire of ins-TGF-beta1 mice was distinct and deviated toward an IL-4-producing Th2 phenotype. When ins-TGF-beta1 mice were treated with anti-iL-4 antibody, islet antigen-specific IFNGamma-producing Th1 cells were unleashed, and the incidence of diabetes increased to the level of NOD mice. This suggests active suppression of a diabetogenic T cell response. This study describes a novel mechanism in which expression of TGF-beta1 in the context of self-antigen shifts APC preference, deviating T cell responses to a Th2 phenotype, preventing IDDM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620681     DOI: 10.1016/s1074-7613(00)80565-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  28 in total

Review 1.  Allograft rejection results from a failed attempt by the immune system to protect foreign tissue.

Authors:  D S Hall; E Roberts; J Davies
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Autoantigen-specific protection of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cells.

Authors:  T Krueger; U Wohlrab; M Klucken; M Schott; J Seissler
Journal:  Diabetologia       Date:  2003-08-20       Impact factor: 10.122

3.  Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo.

Authors:  C Knörr; C Amrehn; H Seeberger; A Rosenwald; S Stilgenbauer; G Ott; H K Müller Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Transgenic expression of TGF-beta on thyrocytes inhibits development of spontaneous autoimmune thyroiditis and increases regulatory T cells in thyroids of NOD.H-2h4 mice.

Authors:  Shiguang Yu; Yujiang Fang; Gordon C Sharp; Helen Braley-Mullen
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

5.  The prospect of induced pluripotent stem cells for diabetes mellitus treatment.

Authors:  Andreas Soejitno; Pande Kadek Aditya Prayudi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

6.  TGF-β and IL-23 gene expression in unstimulated PBMCs of patients with diabetes.

Authors:  Farzaneh Abbasi; Parvin Amiri; Forough A Sayahpour; Saeed Pirmoradi; Milad Abolhalaj; Bagher Larijani; Javad Tavakkoly Bazzaz; Mahsa M Amoli
Journal:  Endocrine       Date:  2011-12-17       Impact factor: 3.633

7.  TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes.

Authors:  Yufeng Peng; Yasmina Laouar; Ming O Li; E Allison Green; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-18       Impact factor: 11.205

8.  Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?

Authors:  Arno Hanninen; Leonard C Harrison
Journal:  Rev Diabet Stud       Date:  2004-11-10

Review 9.  Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.

Authors:  Ayelet Kaminitz; Shifra Ash; Nadir Askenasy
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

10.  Role of complement regulatory proteins in the survival of murine allo-transplanted Sertoli cells.

Authors:  Hak-Mo Lee; Byoung Chol Oh; Dong-Pyo Lim; Dong-Sup Lee; Jaejin Cho; Gene Lee; Jeong Ryul Lee
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.